The UK and US have hammered out a important trade agreement that will guarantee zero tariffs on UK medicine products being sold in the US market.
Agreement Details of the Deal
As part of the deal, the UK has committed to raise spending on pharmaceuticals through the NHS. This move guarantees that import taxes on these crucial goods will be held at zero for a duration of the next three years.
This deal follows recent warnings to dramatically increase tariffs on branded pharmaceutical products, with figures floated reaching double the cost.
"This agreement with the United Kingdom bolsters the global environment for new treatments and brings much-needed equity to U.S.–U.K. drug exports," a release declared.
Trade Significance
Drugs represent one of the Britain's most significant exports to the US, which is clearly the largest destination for major companies like GSK and AstraZeneca.
Trade data show that in the year prior to September, the UK exported pharmaceutical products valued at £11.1bn to the US. This value accounted for a significant portion of total UK exports in that span.
"This guarantee safeguards employment, increases investment and facilitates the UK to emerge as a worldwide center for biotech and pharma," a government official stated.
Key UK Commitments
The pact involves several specific changes from the British government:
- Higher Cost Ceiling: The UK will lift the price threshold at which it considers new medicines to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a goal to increase total NHS spending on drugs from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The sum manufacturers must pay back to the NHS to prevent overspending will be restricted at 15%. Previously, repayments exceeded twenty percent.
Broader Context
This agreement follows a protracted tension between the sector and the ministers over drug pricing and approval rates.
These tensions were exacerbated by claims that US customers were charged significantly more for the equivalent treatments than people in the Britain and the EU.
Over the last 18 months, several major drug company projects in the UK have been delayed or abandoned, while major expansions have been pledged toward US facilities.
The Science Minister publicly accepted that the NHS needed to invest a greater share on drugs, noting that its expenditure on drugs had decreased as a share of its resources over the last ten years.
